ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Long-acting Contraceptive Injection Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: November 2025
|
Report Code: QYRE-Auto-10C17109
Home | Market Reports | Health| Reproductive Health
Global Long acting Contraceptive Injection Market Research Report 2024
BUY CHAPTERS

Global Long-acting Contraceptive Injection Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-10C17109
Report
November 2025
Pages:138
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Bayer
Organon
Merck& Co. Inc
Adare Pharma Solutions
Mylan NV
Merck& Co. Inc

Long-acting Contraceptive Injection Market

The global Long-acting Contraceptive Injection market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
From a downstream perspective, 18-25 Years Old accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Long-acting Contraceptive Injection leading manufacturers including Pfizer, Bayer, Organon, Merck & Co. Inc., Adare Pharma Solutions, Mylan NV, etc., dominate supply; the top five capture approximately % of global revenue, with Pfizer leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Long-acting Contraceptive Injection market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Long-acting Contraceptive Injection Market Report

Report Metric Details
Report Name Long-acting Contraceptive Injection Market
Segment by Type
  • Progesterone
  • Progesterone and Estrogen Combination Preparation
Segment by Application
  • 18-25 Years Old
  • 26-35 Years Old
  • 36-45 Years Old
  • ＞45 Years Old
  • Others
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Pfizer, Bayer, Organon, Merck & Co. Inc., Adare Pharma Solutions, Mylan NV
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Long-acting Contraceptive Injection study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
  • Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 15: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Long-acting Contraceptive Injection Market report?

Ans: The main players in the Long-acting Contraceptive Injection Market are Pfizer, Bayer, Organon, Merck & Co. Inc., Adare Pharma Solutions, Mylan NV

What are the Application segmentation covered in the Long-acting Contraceptive Injection Market report?

Ans: The Applications covered in the Long-acting Contraceptive Injection Market report are 18-25 Years Old, 26-35 Years Old, 36-45 Years Old, ＞45 Years Old, Others

What are the Type segmentation covered in the Long-acting Contraceptive Injection Market report?

Ans: The Types covered in the Long-acting Contraceptive Injection Market report are Progesterone, Progesterone and Estrogen Combination Preparation

1 Study Coverage
1.1 Introduction to Long-acting Contraceptive Injection: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Long-acting Contraceptive Injection Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Progesterone
1.2.3 Progesterone and Estrogen Combination Preparation
1.3 Market Segmentation by Application
1.3.1 Global Long-acting Contraceptive Injection Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 18-25 Years Old
1.3.3 26-35 Years Old
1.3.4 36-45 Years Old
1.3.5 ＞45 Years Old
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Long-acting Contraceptive Injection Revenue Estimates and Forecasts 2020-2031
2.2 Global Long-acting Contraceptive Injection Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Long-acting Contraceptive Injection Sales Estimates and Forecasts 2020-2031
2.4 Global Long-acting Contraceptive Injection Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Long-acting Contraceptive Injection Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Long-acting Contraceptive Injection Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Progesterone Market Size by Manufacturers
3.5.2 Progesterone and Estrogen Combination Preparation Market Size by Manufacturers
3.6 Global Long-acting Contraceptive Injection Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Long-acting Contraceptive Injection Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Long-acting Contraceptive Injection Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Long-acting Contraceptive Injection Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Long-acting Contraceptive Injection Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Long-acting Contraceptive Injection Sales and Revenue by Type (2020-2031)
6.4 North America Long-acting Contraceptive Injection Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Long-acting Contraceptive Injection Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Long-acting Contraceptive Injection Sales and Revenue by Type (2020-2031)
7.4 Europe Long-acting Contraceptive Injection Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Long-acting Contraceptive Injection Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Long-acting Contraceptive Injection Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Long-acting Contraceptive Injection Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Long-acting Contraceptive Injection Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Long-acting Contraceptive Injection Sales and Revenue by Type (2020-2031)
9.4 Central and South America Long-acting Contraceptive Injection Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Long-acting Contraceptive Injection Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Long-acting Contraceptive Injection Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Long-acting Contraceptive Injection Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Long-acting Contraceptive Injection Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Pfizer
11.1.1 Pfizer Corporation Information
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Long-acting Contraceptive Injection Product Models, Descriptions and Specifications
11.1.4 Pfizer Long-acting Contraceptive Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Pfizer Long-acting Contraceptive Injection Sales by Product in 2024
11.1.6 Pfizer Long-acting Contraceptive Injection Sales by Application in 2024
11.1.7 Pfizer Long-acting Contraceptive Injection Sales by Geographic Area in 2024
11.1.8 Pfizer Long-acting Contraceptive Injection SWOT Analysis
11.1.9 Pfizer Recent Developments
11.2 Bayer
11.2.1 Bayer Corporation Information
11.2.2 Bayer Business Overview
11.2.3 Bayer Long-acting Contraceptive Injection Product Models, Descriptions and Specifications
11.2.4 Bayer Long-acting Contraceptive Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Bayer Long-acting Contraceptive Injection Sales by Product in 2024
11.2.6 Bayer Long-acting Contraceptive Injection Sales by Application in 2024
11.2.7 Bayer Long-acting Contraceptive Injection Sales by Geographic Area in 2024
11.2.8 Bayer Long-acting Contraceptive Injection SWOT Analysis
11.2.9 Bayer Recent Developments
11.3 Organon
11.3.1 Organon Corporation Information
11.3.2 Organon Business Overview
11.3.3 Organon Long-acting Contraceptive Injection Product Models, Descriptions and Specifications
11.3.4 Organon Long-acting Contraceptive Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Organon Long-acting Contraceptive Injection Sales by Product in 2024
11.3.6 Organon Long-acting Contraceptive Injection Sales by Application in 2024
11.3.7 Organon Long-acting Contraceptive Injection Sales by Geographic Area in 2024
11.3.8 Organon Long-acting Contraceptive Injection SWOT Analysis
11.3.9 Organon Recent Developments
11.4 Merck & Co. Inc.
11.4.1 Merck & Co. Inc. Corporation Information
11.4.2 Merck & Co. Inc. Business Overview
11.4.3 Merck & Co. Inc. Long-acting Contraceptive Injection Product Models, Descriptions and Specifications
11.4.4 Merck & Co. Inc. Long-acting Contraceptive Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Merck & Co. Inc. Long-acting Contraceptive Injection Sales by Product in 2024
11.4.6 Merck & Co. Inc. Long-acting Contraceptive Injection Sales by Application in 2024
11.4.7 Merck & Co. Inc. Long-acting Contraceptive Injection Sales by Geographic Area in 2024
11.4.8 Merck & Co. Inc. Long-acting Contraceptive Injection SWOT Analysis
11.4.9 Merck & Co. Inc. Recent Developments
11.5 Adare Pharma Solutions
11.5.1 Adare Pharma Solutions Corporation Information
11.5.2 Adare Pharma Solutions Business Overview
11.5.3 Adare Pharma Solutions Long-acting Contraceptive Injection Product Models, Descriptions and Specifications
11.5.4 Adare Pharma Solutions Long-acting Contraceptive Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Adare Pharma Solutions Long-acting Contraceptive Injection Sales by Product in 2024
11.5.6 Adare Pharma Solutions Long-acting Contraceptive Injection Sales by Application in 2024
11.5.7 Adare Pharma Solutions Long-acting Contraceptive Injection Sales by Geographic Area in 2024
11.5.8 Adare Pharma Solutions Long-acting Contraceptive Injection SWOT Analysis
11.5.9 Adare Pharma Solutions Recent Developments
11.6 Mylan NV
11.6.1 Mylan NV Corporation Information
11.6.2 Mylan NV Business Overview
11.6.3 Mylan NV Long-acting Contraceptive Injection Product Models, Descriptions and Specifications
11.6.4 Mylan NV Long-acting Contraceptive Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Mylan NV Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Long-acting Contraceptive Injection Industry Chain
12.2 Long-acting Contraceptive Injection Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Long-acting Contraceptive Injection Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Long-acting Contraceptive Injection Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Long-acting Contraceptive Injection Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Long-acting Contraceptive Injection Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
Bayer
Organon
Merck& Co. Inc
Adare Pharma Solutions
Mylan NV
Merck& Co. Inc
List of Tables
 Table 1. Global Long-acting Contraceptive Injection Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Long-acting Contraceptive Injection Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Long-acting Contraceptive Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Long-acting Contraceptive Injection Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Long-acting Contraceptive Injection Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Global Long-acting Contraceptive Injection Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
 Table 7. Global Long-acting Contraceptive Injection Sales by Region (2020-2025) & (K Units)
 Table 8. Global Long-acting Contraceptive Injection Sales by Region (2026-2031) & (K Units)
 Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 10. Global Long-acting Contraceptive Injection Sales by Manufacturers (2020-2025) & (K Units)
 Table 11. Global Long-acting Contraceptive Injection Sales Share by Manufacturers (2020-2025)
 Table 12. Global Long-acting Contraceptive Injection Revenue by Manufacturers (2020-2025) & (US$ Million)
 Table 13. Global Long-acting Contraceptive Injection Revenue Market Share by Manufacturers (2020-2025)
 Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 15. Global Long-acting Contraceptive Injection by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-acting Contraceptive Injection as of 2024)
 Table 16. Global Long-acting Contraceptive Injection Average Gross Margin (%) by Manufacturer (2020 VS 2024)
 Table 17. Global Long-acting Contraceptive Injection Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
 Table 18. Key Manufacturers Long-acting Contraceptive Injection Manufacturing Base and Headquarters
 Table 19. Global Long-acting Contraceptive Injection Market Concentration Ratio (CR5 and HHI)
 Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 22. Global Long-acting Contraceptive Injection Sales by Type (2020-2025) & (K Units)
 Table 23. Global Long-acting Contraceptive Injection Sales by Type (2026-2031) & (K Units)
 Table 24. Global Long-acting Contraceptive Injection Revenue by Type (2020-2025) & (US$ Million)
 Table 25. Global Long-acting Contraceptive Injection Revenue by Type (2026-2031) & (US$ Million)
 Table 26. Global Long-acting Contraceptive Injection ASP by Type (2020-2031) & (US$/Unit)
 Table 27. Technical Specifications by Key Product Type
 Table 28. Global Long-acting Contraceptive Injection Sales by Application (2020-2025) & (K Units)
 Table 29. Global Long-acting Contraceptive Injection Sales by Application (2026-2031) & (K Units)
 Table 30. Long-acting Contraceptive Injection High-Growth Sectors Demand CAGR (2024-2031)
 Table 31. Global Long-acting Contraceptive Injection Revenue by Application (2020-2025) & (US$ Million)
 Table 32. Global Long-acting Contraceptive Injection Revenue by Application (2026-2031) & (US$ Million)
 Table 33. Global Long-acting Contraceptive Injection ASP by Application (2020-2031) & (US$/Unit)
 Table 34. Top Customers by Region
 Table 35. Top Customers by Application
 Table 36. North America Long-acting Contraceptive Injection Growth Accelerators and Market Barriers
 Table 37. North America Long-acting Contraceptive Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 38. North America Long-acting Contraceptive Injection Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 39. Europe Long-acting Contraceptive Injection Growth Accelerators and Market Barriers
 Table 40. Europe Long-acting Contraceptive Injection Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Europe Long-acting Contraceptive Injection Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 42. Asia-Pacific Long-acting Contraceptive Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 43. Asia-Pacific Long-acting Contraceptive Injection Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 44. Asia-Pacific Long-acting Contraceptive Injection Growth Accelerators and Market Barriers
 Table 45. Southeast Asia Long-acting Contraceptive Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Central and South America Long-acting Contraceptive Injection Investment Opportunities and Key Challenges
 Table 47. Central and South America Long-acting Contraceptive Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 48. Middle East and Africa Long-acting Contraceptive Injection Investment Opportunities and Key Challenges
 Table 49. Middle East and Africa Long-acting Contraceptive Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 50. Pfizer Corporation Information
 Table 51. Pfizer Description and Major Businesses
 Table 52. Pfizer Product Models, Descriptions and Specifications
 Table 53. Pfizer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 54. Pfizer Sales Value Proportion by Product in 2024
 Table 55. Pfizer Sales Value Proportion by Application in 2024
 Table 56. Pfizer Sales Value Proportion by Geographic Area in 2024
 Table 57. Pfizer Long-acting Contraceptive Injection SWOT Analysis
 Table 58. Pfizer Recent Developments
 Table 59. Bayer Corporation Information
 Table 60. Bayer Description and Major Businesses
 Table 61. Bayer Product Models, Descriptions and Specifications
 Table 62. Bayer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 63. Bayer Sales Value Proportion by Product in 2024
 Table 64. Bayer Sales Value Proportion by Application in 2024
 Table 65. Bayer Sales Value Proportion by Geographic Area in 2024
 Table 66. Bayer Long-acting Contraceptive Injection SWOT Analysis
 Table 67. Bayer Recent Developments
 Table 68. Organon Corporation Information
 Table 69. Organon Description and Major Businesses
 Table 70. Organon Product Models, Descriptions and Specifications
 Table 71. Organon Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 72. Organon Sales Value Proportion by Product in 2024
 Table 73. Organon Sales Value Proportion by Application in 2024
 Table 74. Organon Sales Value Proportion by Geographic Area in 2024
 Table 75. Organon Long-acting Contraceptive Injection SWOT Analysis
 Table 76. Organon Recent Developments
 Table 77. Merck & Co. Inc. Corporation Information
 Table 78. Merck & Co. Inc. Description and Major Businesses
 Table 79. Merck & Co. Inc. Product Models, Descriptions and Specifications
 Table 80. Merck & Co. Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 81. Merck & Co. Inc. Sales Value Proportion by Product in 2024
 Table 82. Merck & Co. Inc. Sales Value Proportion by Application in 2024
 Table 83. Merck & Co. Inc. Sales Value Proportion by Geographic Area in 2024
 Table 84. Merck & Co. Inc. Long-acting Contraceptive Injection SWOT Analysis
 Table 85. Merck & Co. Inc. Recent Developments
 Table 86. Adare Pharma Solutions Corporation Information
 Table 87. Adare Pharma Solutions Description and Major Businesses
 Table 88. Adare Pharma Solutions Product Models, Descriptions and Specifications
 Table 89. Adare Pharma Solutions Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 90. Adare Pharma Solutions Sales Value Proportion by Product in 2024
 Table 91. Adare Pharma Solutions Sales Value Proportion by Application in 2024
 Table 92. Adare Pharma Solutions Sales Value Proportion by Geographic Area in 2024
 Table 93. Adare Pharma Solutions Long-acting Contraceptive Injection SWOT Analysis
 Table 94. Adare Pharma Solutions Recent Developments
 Table 95. Mylan NV Corporation Information
 Table 96. Mylan NV Description and Major Businesses
 Table 97. Mylan NV Product Models, Descriptions and Specifications
 Table 98. Mylan NV Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 99. Mylan NV Recent Developments
 Table 100. Key Raw Materials Distribution
 Table 101. Raw Materials Key Suppliers
 Table 102. Critical Raw Material Supplier Concentration (2024) & Risk Index
 Table 103. Milestones in Production Technology Evolution
 Table 104. Distributors List
 Table 105. Market Trends and Market Evolution
 Table 106. Market Drivers and Opportunities
 Table 107. Market Challenges, Risks, and Restraints
 Table 108. Research Programs/Design for This Report
 Table 109. Key Data Information from Secondary Sources
 Table 110. Key Data Information from Primary Sources


List of Figures
 Figure 1. Long-acting Contraceptive Injection Product Picture
 Figure 2. Global Long-acting Contraceptive Injection Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Progesterone Product Picture
 Figure 4. Progesterone and Estrogen Combination Preparation Product Picture
 Figure 5. Global Long-acting Contraceptive Injection Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 6. 18-25 Years Old
 Figure 7. 26-35 Years Old
 Figure 8. 36-45 Years Old
 Figure 9. ＞45 Years Old
 Figure 10. Others
 Figure 11. Long-acting Contraceptive Injection Report Years Considered
 Figure 12. Global Long-acting Contraceptive Injection Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global Long-acting Contraceptive Injection Revenue (2020-2031) & (US$ Million)
 Figure 14. Global Long-acting Contraceptive Injection Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 15. Global Long-acting Contraceptive Injection Revenue Market Share by Region (2020-2031)
 Figure 16. Global Long-acting Contraceptive Injection Sales (2020-2031) & (K Units)
 Figure 17. Global Long-acting Contraceptive Injection Sales (CAGR) by Region (2020-2031) (K Units)
 Figure 18. Global Long-acting Contraceptive Injection Sales Market Share by Region (2020-2031)
 Figure 19. Top 5 and Top 10 Manufacturers Long-acting Contraceptive Injection Sales Volume Market Share in 2024
 Figure 20. Global Long-acting Contraceptive Injection Revenue Market Share Ranking (2024)
 Figure 21. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 22. Progesterone Revenue Market Share by Manufacturer in 2024
 Figure 23. Progesterone and Estrogen Combination Preparation Revenue Market Share by Manufacturer in 2024
 Figure 24. Global Long-acting Contraceptive Injection Sales Market Share by Type (2020-2031)
 Figure 25. Global Long-acting Contraceptive Injection Revenue Market Share by Type (2020-2031)
 Figure 26. Global Long-acting Contraceptive Injection Sales Market Share by Application (2020-2031)
 Figure 27. Global Long-acting Contraceptive Injection Revenue Market Share by Application (2020-2031)
 Figure 28. North America Long-acting Contraceptive Injection Sales YoY (2020-2031) & (K Units)
 Figure 29. North America Long-acting Contraceptive Injection Revenue YoY (2020-2031) & (US$ Million)
 Figure 30. North America Top 5 Manufacturers Long-acting Contraceptive Injection Sales Revenue (US$ Million) in 2024
 Figure 31. North America Long-acting Contraceptive Injection Sales Volume (K Units) by Type (2020- 2031)
 Figure 32. North America Long-acting Contraceptive Injection Sales Revenue (US$ Million) by Type (2020 - 2031)
 Figure 33. North America Long-acting Contraceptive Injection Sales Volume (K Units) by Application (2020-2031)
 Figure 34. North America Long-acting Contraceptive Injection Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 35. US Long-acting Contraceptive Injection Revenue (2020-2031) & (US$ Million)
 Figure 36. Canada Long-acting Contraceptive Injection Revenue (2020-2031) & (US$ Million)
 Figure 37. Mexico Long-acting Contraceptive Injection Revenue (2020-2031) & (US$ Million)
 Figure 38. Europe Long-acting Contraceptive Injection Sales YoY (2020-2031) & (K Units)
 Figure 39. Europe Long-acting Contraceptive Injection Revenue YoY (2020-2031) & (US$ Million)
 Figure 40. Europe Top 5 Manufacturers Long-acting Contraceptive Injection Sales Revenue (US$ Million) in 2024
 Figure 41. Europe Long-acting Contraceptive Injection Sales Volume (K Units) by Type (2020-2031)
 Figure 42. Europe Long-acting Contraceptive Injection Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 43. Europe Long-acting Contraceptive Injection Sales Volume (K Units) by Application (2020-2031)
 Figure 44. Europe Long-acting Contraceptive Injection Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 45. Germany Long-acting Contraceptive Injection Revenue (2020-2031) & (US$ Million)
 Figure 46. France Long-acting Contraceptive Injection Revenue (2020-2031) & (US$ Million)
 Figure 47. U.K. Long-acting Contraceptive Injection Revenue (2020-2031) & (US$ Million)
 Figure 48. Italy Long-acting Contraceptive Injection Revenue (2020-2031) & (US$ Million)
 Figure 49. Russia Long-acting Contraceptive Injection Revenue (2020-2031) & (US$ Million)
 Figure 50. Asia-Pacific Long-acting Contraceptive Injection Sales YoY (2020-2031) & (K Units)
 Figure 51. Asia-Pacific Long-acting Contraceptive Injection Revenue YoY (2020-2031) & (US$ Million)
 Figure 52. Asia-Pacific Top 8 Manufacturers Long-acting Contraceptive Injection Sales Revenue (US$ Million) in 2024
 Figure 53. Asia-Pacific Long-acting Contraceptive Injection Sales Volume (K Units) by Type (2020- 2031)
 Figure 54. Asia-Pacific Long-acting Contraceptive Injection Sales Revenue (US$ Million) by Type (2020- 2031)
 Figure 55. Asia-Pacific Long-acting Contraceptive Injection Sales Volume (K Units) by Application (2020-2031)
 Figure 56. Asia-Pacific Long-acting Contraceptive Injection Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 57. Indonesia Long-acting Contraceptive Injection Revenue (2020-2031) & (US$ Million)
 Figure 58. Japan Long-acting Contraceptive Injection Revenue (2020-2031) & (US$ Million)
 Figure 59. South Korea Long-acting Contraceptive Injection Revenue (2020-2031) & (US$ Million)
 Figure 60. China Taiwan Long-acting Contraceptive Injection Revenue (2020-2031) & (US$ Million)
 Figure 61. India Long-acting Contraceptive Injection Revenue (2020-2031) & (US$ Million)
 Figure 62. Central and South America Long-acting Contraceptive Injection Sales YoY (2020-2031) & (K Units)
 Figure 63. Central and South America Long-acting Contraceptive Injection Revenue YoY (2020-2031) & (US$ Million)
 Figure 64. Central and South America Top 5 Manufacturers Long-acting Contraceptive Injection Sales Revenue (US$ Million) in 2024
 Figure 65. Central and South America Long-acting Contraceptive Injection Sales Volume (K Units) by Type (2021-2031)
 Figure 66. Central and South America Long-acting Contraceptive Injection Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 67. Central and South America Long-acting Contraceptive Injection Sales Volume (K Units) by Application (2020-2031)
 Figure 68. Central and South America Long-acting Contraceptive Injection Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 69. Brazil Long-acting Contraceptive Injection Revenue (2020-2025) & (US$ Million)
 Figure 70. Argentina Long-acting Contraceptive Injection Revenue (2020-2025) & (US$ Million)
 Figure 71. Middle East, and Africa Long-acting Contraceptive Injection Sales YoY (2020-2031) & (K Units)
 Figure 72. Middle East and Africa Long-acting Contraceptive Injection Revenue YoY (2020-2031) & (US$ Million)
 Figure 73. Middle East and Africa Top 5 Manufacturers Long-acting Contraceptive Injection Sales Revenue (US$ Million) in 2024
 Figure 74. Middle East and Africa Long-acting Contraceptive Injection Sales Volume (K Units) by Type (2021-2031)
 Figure 75. South America Long-acting Contraceptive Injection Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 76. Middle East and Africa Long-acting Contraceptive Injection Sales Volume (K Units) by Application (2020-2031)
 Figure 77. Middle East and Africa Long-acting Contraceptive Injection Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 78. GCC Countries Long-acting Contraceptive Injection Revenue (2020-2025) & (US$ Million)
 Figure 79. Turkey Long-acting Contraceptive Injection Revenue (2020-2025) & (US$ Million)
 Figure 80. Egypt Long-acting Contraceptive Injection Revenue (2020-2025) & (US$ Million)
 Figure 81. South Africa Long-acting Contraceptive Injection Revenue (2020-2025) & (US$ Million)
 Figure 82. Long-acting Contraceptive Injection Industry Chain Mapping
 Figure 83. Regional Long-acting Contraceptive Injection Manufacturing Base Distribution (%)
 Figure 84. Global Long-acting Contraceptive Injection Production Market Share by Region (2020-2031)
 Figure 85. Long-acting Contraceptive Injection Production Process
 Figure 86. Regional Long-acting Contraceptive Injection Production Cost Structure
 Figure 87. Channels of Distribution (Direct Vs Distribution)
 Figure 88. Bottom-up and Top-down Approaches for This Report
 Figure 89. Data Triangulation
 Figure 90. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Samsung SD

SIMILAR REPORTS

Global Long acting Hormone Injection Market Research Report 2024
Contraceptive Injectable Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Psychiatric Long acting Injection Market Research Report 2024
Global Female Contraception Market Research Report 2024
Global Long acting Anti HIV Drug Market Research Report 2024
Long acting Injectable Medications Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Long Acting Contraceptive Pills Market Research Report 2024
Short Acting Contraceptives Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Special Injection Market Research Report 2025
Long acting Reversible Contraceptives LARCs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Eye Injection Market Research Report 2024
Contraceptive Pills Market
Global Female Contraception Drug Market Research Report 2024
Global Female Contraceptive Pill Market Insights Forecast to 2030
Global Progesterone Injection Market Research Report 2024
Global Anticancer Injection Market Research Report 2024
Global Oral Contraceptive Market Research Report 2024
Global Sterile Injection Development Market Research Report 2025
Global Injection Machines Market Research Report 2024
Global Lixisenatide Injection Market Research Report 2024

RELATED REPORTS

Global Foetal Skull Model Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-8G20187
Fri Nov 28 00:00:00 UTC 2025

Add to Cart

Global Anatomy Set Pregnancy Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-30J19782
Sat Nov 22 00:00:00 UTC 2025

Add to Cart

Global Embryo Model Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-39D19945
Sat Nov 22 00:00:00 UTC 2025

Add to Cart

Global Prostate Model Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-25M19897
Sat Nov 22 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions